Nivolumab melanoma trial studies - Select GI AEs Managed in Studies of Nivolumab
Results from the phase II, double-blind CheckMate-069 clinical trial showed unprecedented response rates with ipilimumab combined with nivolumab in previously treated patients with metastatic melanoma.
This trial is for people over the age of 15 who have had surgery to completely remove their melanoma skin cancer (complete resection).
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? studies in advanced melanoma.
Nivolumab (Opdivo ) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The
A summary of results from an international, double-blind, randomized phase III trial testing the combination of nivolumab (Opdivo) against nivolumab alone and ipilimumab alone in patients with advanced melanoma.
Background In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial.